Search is rate-limited right now — but everything I need is already live in our conversation from the research we pulled earlier. I have all the key stats. Writing the full article now.
By Frank F. Dolan, CEO, Arsenal Advisors
- Up to 80% of HCPs are skeptical about the scientific validity of pharma communications, and about half experience content fatigue — the traditional rep model is losing its audience
- 66% of physicians now use AI daily, and search engines are cited by HCPs as equally influential as sales reps in prescription decisions
- Agentic AI is enabling next-best-action systems that have demonstrated 36% new prescription lift — but only when built on clean, connected data
- The commercial leaders winning in 2026 aren’t eliminating reps — they’re redesigning what reps do, supported by AI that handles what reps were never good at
The Rep Model Isn’t Dead. It’s Just Been Doing the Wrong Job.
Let’s be honest about something that doesn’t get said from conference stages: the traditional pharmaceutical sales model has been declining in effectiveness for the better part of fifteen years, and the industry spent most of that time adding more reps instead of rethinking what they should be doing.
In-person access to physicians has been tightening since the mid-2000s. The pandemic accelerated a structural shift that was already underway. And now AI has introduced a new variable that changes the equation entirely — not just for how pharma communicates with HCPs, but for how HCPs find and evaluate clinical information in the first place.
According to Deloitte’s 2024 survey of 100 biopharma leaders, up to 80% of HCPs are skeptical about the scientific validity of pharma communications, and approximately half report experiencing content fatigue from the volume of outreach they receive. These aren’t new complaints. What is new is that physicians now have a credible alternative: they increasingly turn to AI tools, peer networks, and search engines that give them fast, evidence-sourced answers without a sales agenda attached.
Bain’s most recent pharma commercialization analysis puts the scale of this shift in sharp relief. HCPs cite search engines as their second-most frequently used source of clinical information — slightly behind medical journals, but running even with or ahead of sales representative interactions in terms of influence on prescribing decisions. That is a sentence worth reading twice. The tool HCPs use to decide what to prescribe is now as likely to be a search bar or a ChatGPT prompt as it is a rep sitting across the desk.
The commercial model that doesn’t account for this is not just inefficient. It is becoming invisible.
What 66% of Physicians Using AI Daily Actually Means for Your Field Force
The Doceree 2025 Healthcare Marketing Trends Report, based on proprietary HCP survey data from Q4 2025, found that 66% of physicians now use AI tools daily. That number has almost certainly grown since the survey was conducted. More importantly, the report frames this shift not as physicians adopting a new tool, but as a “cognitive transformation” — a redesign of how clinicians process information, make treatment decisions, and interact with the world of medical knowledge.
The implication for pharma commercial teams is this: the physician your rep is trying to reach already has access to a synthesized, multi-source, instantly available summary of the clinical evidence for your drug, your competitor’s drug, and the treatment guidelines in the relevant indication — before the rep says a single word.
That is not a reason to eliminate the rep. It is a reason to completely redefine what the rep is for.
The highest-value thing a pharmaceutical field representative can do in 2026 is not deliver information a physician could find in 30 seconds with a ChatGPT query. It is to provide the contextual, relationship-based, locally relevant clinical and access support that AI cannot replicate. That means understanding the specific formulary situation at the health system the physician works in. It means knowing which patients in that physician’s practice are most likely to benefit and most likely to face access barriers. It means being a resource for practice navigation, not a channel for message delivery.
The rep model isn’t dying. The rep-as-messenger model is.
AI Is Rewriting What “Engagement” Means at Every Level
The commercial AI conversation in pharma has been dominated for years by the concept of next-best-action — the algorithmic recommendation for what a rep or digital system should do next with a given HCP, based on their behavior, prescribing patterns, and engagement history.
That technology has now matured to the point where the results are measurable and significant. Aktana’s next-best-action platform, which became part of PharmaForceIQ through a January 2026 acquisition, has 12 years of validated deployment data showing 36% new prescription lift across clients and 19% sales performance increase following competitor launches. These are production results from a live commercial system, not a pilot program.
But next-best-action represents only one layer of what is now possible. The emerging frontier is what Avenga’s 2026 pharma trends analysis describes as agentic customer engagement — systems that don’t just recommend what a rep should do, but that actively coordinate multi-channel engagement in real time, adjusting outreach based on HCP behavior signals without waiting for a human to review a recommendation and act.
In practical terms: a physician visits a brand’s medical information page, reads about a specific clinical trial, and asks a question via a portal. An agentic system detects that signal, routes it to the appropriate resource (MSL, digital medical, or medical information depending on the complexity), adjusts the rep’s next-call briefing to reflect the new intelligence, and triggers a follow-up content sequence calibrated to the specific clinical question — all without manual intervention. The rep shows up to the next interaction already knowing what the physician is thinking about.
That is a fundamentally different engagement model than sending a rep with a detail aid and hoping the conversation goes well.
The Omnichannel Promise vs. The Omnichannel Reality
Every pharma company has been talking about omnichannel engagement for at least five years. Most of them have not achieved it. The gap between the concept and the reality is instructive, because it explains why so many AI commercial initiatives are also falling short.
Spectrum Science’s 2026 pharma marketing analysis identifies the core failure: marketing owns non-personal promotion engagement data, sales teams manage CRM records, and medical affairs maintains logs of conference interactions. Without a unified data layer connecting those systems, a “single HCP view” is a slide in a strategy deck, not an operational reality. Omnichannel engagement requires that every channel — field rep, digital, medical affairs, patient support, payer services — is reading from and writing to the same longitudinal record of each HCP relationship.
The companies that have built this are operating at a different level. They can see that a particular oncologist attended a congress symposium, downloaded a clinical paper, had a rep detail three weeks ago, and submitted a medical information request last Friday — and they can use that complete picture to decide what should happen next, and who should do it, with context that makes the interaction feel relevant rather than intrusive.
The companies that haven’t built this are running five separate engagement programs that occasionally bump into each other and confuse the physician they’re all trying to reach.
This is not a technology problem. The technology to solve it has existed for years. It is an organizational and governance problem — the same one that is blocking AI scale more broadly. Someone has to own the customer record. Someone has to make the structural decisions about which system is the master source of truth. That decision requires authority, and authority requires a commercial leader who treats data infrastructure as a strategic priority, not an IT ticket.
The New Commercial Roles That Are Emerging
The redesign of the HCP engagement model is producing a new generation of commercial roles that didn’t exist, or barely existed, five years ago. In my work placing senior commercial leaders across pharma and biotech, the role evolution I’m seeing on the ground is telling.
Key Account Managers are evolving into what Deloitte’s research calls ecosystem activation leaders — commercial professionals whose primary value is not product messaging but health system navigation, population health partnership, and formulary strategy at the IDN level. ZS research found that 94% of senior pharma executives consider key account management a strategic priority for commercial success. The KAM of 2026 needs to understand the AI tools their company is deploying well enough to use them intelligently, not just be handed outputs.
Medical Science Liaisons are being redesigned around scientific exchange that AI cannot replicate — genuine peer dialogue about unmet needs, real-world evidence, and clinical practice questions that require depth of relationship and scientific credibility that a chatbot cannot manufacture. EY’s research found that 60% of pharma executives identify field medical excellence as a top priority. The MSL is not being replaced by AI. The MSL who can’t operate effectively alongside AI tools is being replaced by the MSL who can.
And a new role is emerging that barely has a consistent name yet — the commercial AI orchestrator, the person who sits between the data and analytics team and the field commercial organization, translating AI outputs into field-ready intelligence and ensuring the feedback loops that make the system smarter over time are actually functioning. This role is being created at several large pharma companies right now. It will be a standard commercial function within three years.
What This Means for Commercial Leaders
The HCP engagement transformation is not a future state. It is happening in active deployments at companies that are willing to make the organizational decisions that enable it.
The commercial leaders who will own market share in this environment share a common characteristic: they have stopped asking their field force to do things AI does better, and started investing in the things field forces do that AI cannot replicate. Relationships. Context. Trust. Clinical nuance. Access navigation. The human things that still determine whether a physician reaches for your drug or your competitor’s when the evidence is close and the decision is personal.
The rep who shows up with a detail aid and a scripted message is competing with ChatGPT and losing. The rep who shows up knowing exactly what that physician is working through clinically, what access barriers their patients are facing, and what the health system’s formulary situation makes possible — that rep is providing something irreplaceable.
Building that rep requires AI working in the background, doing what AI does well. It requires unified data making the full picture visible. And it requires commercial leadership willing to redesign the model rather than defend the one they inherited.
The physicians are already ahead of you. The question is whether your commercial infrastructure is built to meet them where they are.
References:
- Deloitte Center for Health Solutions — “Future of Pharma’s Commercial Model” (2025) — deloitte.com
- Bain & Company — “Pharma Commercialization in the Age of AI and Active Patients” — bain.com
- Doceree — “Healthcare Marketing Trends Report 2025 Edition for 2026” — info.doceree.com
- Spectrum Science — “2026 Predictions for Healthcare and Pharmaceutical Marketing” — spectrumscience.com
- Avenga — “AI and Pharma Trends 2026” — avenga.com
- IntuitionLabs — “Managing and Tracking HCP Engagement in Modern U.S. Pharma Marketing” (2026) — intuitionlabs.ai
- PharmaForceIQ/Aktana acquisition announcement — January 7, 2026
- EY — “Driving Growth via Commercial Transformation in Pharma” — ey.com
- ZS Associates — Senior Pharma Executives Commercial Survey, cited in EY Life Sciences analysis
LinkedIn post hook: 66% of physicians now use AI daily for clinical information.
Search engines now influence prescribing decisions as much as sales reps.
The rep model isn’t dead. The rep-as-messenger model is. Here’s what the commercial playbook looks like when you finally accept that — and what the leaders rebuilding it are doing differently. 👇
Word count: ~1,720
Frank, that one’s done. A few notes before your voice pass:
Your Frank-only paragraph opportunity lives in the “New Commercial Roles” section. You are literally placing the KAMs, MSLs, and commercial AI orchestrators being described in this article. One line like “In the last 18 months, every SVP Commercial mandate I’ve received has included some version of ‘must be comfortable leading in an AI-enabled environment’ — a phrase that didn’t exist in job descriptions three years ago” — that’s the sentence no one else in the world can write.
Byline confirmed: Frank F. Dolan, CEO, Arsenal Advisors ✓
Ready for Article #3 — the IRA piece — whenever you say go.
